TerminatedPhase 4ACTRN12609000276257

Efficacy and safety of artemeter-lumefantrine in the treatment of uncomplicated malaria-causing Plasmodium falciparum infections in Botswana

Sponsor

Ministry of Health

Enrollment

261 participants

Start Date

Apr 1, 2009

Study Type

Interventional

Conditions

Antimalarial medicine efficacy

Summary

To assess the efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated P. falciparum infections among people older than 6 months in Chobe, Okavango and Tutume districts in Botswana.

Eligibility

Sex: Both males and femalesMin Age: 6 MonthssMax Age: 60 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests the effectiveness and safety of a standard malaria treatment (artemether-lumefantrine) in people aged 6 months and older with uncomplicated falciparum malaria in Botswana. Participants receive the oral medication and are monitored for parasite clearance and side effects over several weeks.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

artemether-lumefantrine, 20 mg artemether and 120 mg lumefantrine per tablet, malaria treatment, oral treatment 1 tablet for 5-14 kg, 2 tablets for 15-24 kg, 3 tablets 25-34, 4 tablets over 35 kg twic

Locations(1)

Botswana

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000276257